Lundbeck´s VYEPTITM (eptinezumab-jjmr), Quarterly Treatment for Migraine Prevention in Adults, Now Available in U.S.
(WorldNews Business)

DEERFIELD, Ill.--(BUSINESS WIRE)--Apr 6, 2020-- Lundbeck today announced that VYEPTITM (eptinezumab-jjmr), the first and only intravenous (IV) treatment for migraine prevention, is now commercially available in the U.S. and can be obtained via select specialty distributors and specialty pharmacies. `We are pleased to announce the availability of VYEPTI for migraine prevention in the U.S., along with a suite of online resources for patients and their healthcare providers, which we hope will be useful to learn more about this new treatment option,` said Peter Anastasiou, Lundbeck´s Executive Vice President, North America. `While we recognize and face the challenges of this global pandemic...